Autolus Therapeutics (AUTL)

Executive Summary

Autolus Therapeutics is a clinical-stage biopharmaceutical company pioneering next-generation programmed autologous CAR T-cell therapies for cancer and autoimmune diseases. Its lead product, obecabtagene autoleucel (obe-cel), is approved in the US and Europe for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), offering a differentiated safety and efficacy profile. The company is now leveraging its proprietary platform to expand into autoimmune indications, with ongoing Phase 2 trials in lupus nephritis and Phase 1 trials in progressive multiple sclerosis. Autolus also has early-stage pipeline assets including AUTO1 for additional hematologic malignancies. Commercial launch of obe-cel is underway, and investor focus is on uptake and expansion into larger autoimmune markets. With a strong scientific foundation and first-mover advantage in autoimmune CAR T, Autolus is positioned for growth, though near-term revenues remain modest.

Upcoming Catalysts (preview)

• Q3 2026Obe-cel initial sales and prescription trends for B-ALL80% success
• Q1 2027Phase 2 data readout of obe-cel in lupus nephritis55% success
• Q4 2026Initiation of pivotal trial for obe-cel in multiple sclerosis40% success